ライフサイエンスコーパス: lupus anticoagulant

1 d anti-phosphatidyl-serine) and 1 in plasma (lupus anticoagulant).

2 reviously reported to be associated with the lupus anticoagulant.

3 n increased thrombotic risk in patients with lupus anticoagulant.

4 differed in sensitivity to the presence of a lupus anticoagulant.

5 he clotting test is used in the diagnosis of lupus anticoagulants.

6 mbin times is invalid for some patients with lupus anticoagulants.

7 monitored with a test that is insensitive to lupus anticoagulants.

8 Both monoclonal autoantibodies lacked lupus anticoagulant activity and did not inhibit prothro

9 hrombosis and women in the upper quartile of lupus anticoagulant activity had the highest risk.

10 ody was analyzed for its binding properties, lupus anticoagulant activity, and pathophysiologic activ

11 red endothelial cells in vitro, and some had lupus anticoagulant activity.

12 olamine, and phosphatidylserine), and showed lupus anticoagulant activity.

13 phospholipids/cofactors and vary in in vitro lupus anticoagulant activity.

14 Lupus anticoagulant and ACAs are made up of heterogeneou

15 present with thrombosis and are positive for lupus anticoagulant and ACAs have similar clinical prese

16 Isolated lupus anticoagulant and ACAs in children who are asympto

17 6.6%) were positive for aPL because they had lupus anticoagulant and/or high titer of anticardiolipin

18 Lupus anticoagulants and anticardiolipin antibodies have

19 n antigen specificities of autoantibodies in lupus anticoagulants and the mechanisms by which these a

20 bodies including anticardiolipin antibodies, lupus anticoagulants, and anti-beta(2) glycoprotein-1-sp

21 We report here experiments on how lupus anticoagulant antibodies (LA IgG) that react with

22 I, fibrinogen, lipoprotein(a), homocysteine, lupus anticoagulant, anticardiolipin antibodies and geno

23 ecurrent fetal loss, and the presence of the lupus anticoagulant, anticardiolipin antibodies, or anti

24 ntial investigations include measurements of lupus anticoagulant, anticardiolipin antibodies, thyroid

25 All patients who had positive results of lupus anticoagulant, anticardiolipin, and anti-beta(2)-g

26 y was associated with triple positivity (for lupus anticoagulant, anticardiolipin, and anti-beta2GPI

27 Reactive antibodies to lupus anticoagulant, anticardiolipin, antithrombin III,

28 owever, establish that the autoantibodies in lupus anticoagulants are not directed against "native" a

29 n enzyme-linked immunosorbent assay (ELISA), lupus anticoagulant assays, and syphilis screening in ch

30 Lupus anticoagulants can influence prothrombin times and

31 Lupus anticoagulants comprise a heterogenous group of ci

32 ossibly the same epitope associated with the lupus anticoagulant, defined a small subset of children

33 annexin V, stands in marked contrast to the "lupus anticoagulant effect" previously described in thes

34 POmAb is an anticoagulant but exerts a weak lupus anticoagulant effect.

35 All tested positive for lupus anticoagulant, had IgM antibodies to cardiolipin,

36 Yet, despite treatment, those positive for lupus anticoagulant have at least a 30% likelihood of ad

37 A lupus anticoagulant immunoglobulin was more inhibitory t

38 ardiolipin > or =40 IU/ml or the presence of lupus anticoagulant) in 42 patients (21%).

39 ting 151 patients with persistently positive lupus anticoagulant (LA) for a median period of 8.2 year

40 Nineteen of 28 patients with APS had lupus anticoagulant (LA) or high titers of anticardiolip

41 Data on the clinical course of lupus anticoagulant (LA)-positive individuals with or wi

42 10-2015 we identified individuals tested for lupus anticoagulant(LA), anti-cardiolipin (aCL), and ant

43 line predictors of APOs included presence of lupus anticoagulant (LAC) (odds ratio [OR], 8.32 [CI, 3.

44 glycerides (all P < 0.0001), and presence of lupus anticoagulant (LAC) (P = 0.045) were associated wi

45 pid antibodies under the perception that the lupus anticoagulant (LAC) is prevalent in this populatio

46 e Caucasian ethnicity, smoking, alcohol use, lupus anticoagulant (LAC) positivity, and renal involvem

47 dsDNA], anti-Sm, anti-Ro, anti-La, anti-RNP, lupus anticoagulant (LAC), and anticardiolipin antibody

48 esence of antiphospholipid antibodies (aPL), lupus anticoagulant (LAC), anti-beta2GPI antibody, and t

49 ence of anti-phospholipid (PL) Ab, including lupus anticoagulants (LAC) and/or anticardiolipin Ab (aC

50 Recent data suggest strongly that lupus anticoagulants (LACs) and anticardiolipin antibodi

51 Patients with lupus anticoagulants often have a prolonged prothrombin

52 well as elevated anticardiolipin antibodies, lupus anticoagulant, or a history compatible with antiph

53 r high levels of anticardiolipin antibodies, lupus anticoagulant, or a history of thrombosis.

54 level, were hypertensive, were positive for lupus anticoagulant, or had proteinuria.

55 with high-titer anticardiolipin antibodies, lupus anticoagulant, or previous thrombosis.

56 significantly associated with positivity for lupus anticoagulant (P < 0.0001) and anticardiolipin ant

57 trols, CVD patients were more likely to have lupus anticoagulant (P = 0.03), but less likely to be re

58 likely to have antiphospholipid antibodies (lupus anticoagulant) (P = 0.01).

59 and persistently positive anticardiolipin or lupus anticoagulant positive tests.

60 on laboratory and clinical manifestations of lupus anticoagulants, the pathogenetic mechanisms involv

61 id syndrome includes elevation of either the lupus anticoagulant titer or the anticardiolipin antibod

62 ody was 1.53 (95% CI, 0.76-3.11), and with a lupus anticoagulant was 2.83 (95% CI, 0.83-9.64).

63 Lupus anticoagulant was a risk factor for unprovoked pro

64 A lupus anticoagulant was detected in four of five evaluat

65 s) for oral anticoagulation in patients with lupus anticoagulants who sustain a thromboembolic event

66 For patients with lupus anticoagulants who were not receiving warfarin, pr